Mylan prevails in Copaxone® 40mg/mL litigation against Teva in U.S. Appellate Court
Mylan announced the U.S. Court of Appeals for the Federal Circuit has affirmed the District of Delaware's decision that Teva's Copaxone® 40 mg/mL dosing patents are invalid as obvious. The Federal Circuit also affirmed the final written decisions issued by the Patent Trial and Appeal Board. October 12, 2018